Strata Critical Medical (NASDAQ:SRTA) is set to give its latest quarterly earnings report on Tuesday, 2026-03-03. Here's what investors need to know before the announcement.

Analysts estimate that Strata Critical Medical will report an earnings per share (EPS) of $-0.04.

Investors in Strata Critical Medical are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Performance in Previous Earnings

In the previous earnings release, the company missed EPS by $0.10, leading to a 3.92% increase in the share price the following trading session.

Here's a look at Strata Critical Medical's past performance and the resulting price change:

Stock Performance

Shares of Strata Critical Medical were trading at $4.28 as of February 27. Over the last 52-week period, shares are up 39.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Get to Know Strata Critical Medical Better

Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. Its core services include air and ground logistics, surgical organ recovery, organ placement, and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.

Key Indicators: Strata Critical Medical's Financial Health

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Strata Critical Medical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 36.7%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Strata Critical Medical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 116.47% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 22.69%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): Strata Critical Medical's ROA excels beyond industry benchmarks, reaching 19.36%. This signifies efficient management of assets and strong financial health.

Debt Management: With a below-average debt-to-equity ratio of 0.01, Strata Critical Medical adopts a prudent financial strategy, indicating a balanced approach to debt management.

To track all earnings releases for Strata Critical Medical visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.